BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Pharmacogenetics
,
Clofibrate
,
rs2230926
,
EGFR
,
T cell differentiation
,
Leukemia
,
Breast
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
benign neonatal convulsions
(phenotype)
Summary
General Info
Genetic Markers
Most Correlated Genes
Most Correlated SNPs
SCN2A
No SNPs found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS
transmission of nerve impulse
REACTOME_L1CAM_INTERACTIONS
Ion transport domain
GSE18281_CORTICAL_THYMOCYTE_VS_WHOLE_CORTEX_THYMUS_UP
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Mouse Phenotypes - Epilepsy
OMIM - Epilepsy
Explore Curated Studies Results
Literature
Most Relevant Literature
Novel KCNQ2 mutation in a large Emirati family with benign familial neonatal seizures.
KCNQ2 abnormality in BECTS: benign childhood epilepsy with centrotemporal spikes following benign ne…
Benign familial neonatal convulsions: A family with a rare disorder.
Novel mutation in KCNQ2 causing benign familial neonatal seizures.
Benign familial neonatal convulsions: novel mutation in a newborn.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy
Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission
Investigation of the Efficacy and Safety of CHI-921 in Insomnia.
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Mon…
Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ